Upstream Bio (UPB) EBIT (2023 - 2026)
Upstream Bio (UPB) posted quarterly EBIT of -$43.6 million for Q1 2026, down 36.24% year-over-year from -$68.4 million in Q1 2025, and up 5.53% quarter-over-quarter from -$46.2 million in Q4 2025.
Upstream Bio (UPB) EBIT (2023 - 2026) Analysis & Trends
Upstream Bio's EBIT history runs 4 years deep, the most recent figure standing at -$43.6 million for Q1 2026.
- In Q1 2026, EBIT fell 36.24% year-over-year to -$43.6 million; the TTM figure through Mar 2026 stood at -$172.0 million (down 81.46% YoY), while the FY2025 annual figure was -$160.4 million, down 106.21% from the prior year.
- EBIT for Q1 2026 stood at -$43.6 million, up from -$46.2 million in the prior quarter.
- The five-year high for EBIT was -$9.4 million in Q3 2023, with the low at -$46.2 million in Q4 2025.
- The 4-year median for EBIT is -$26.3 million (2024), against an average of -$27.8 million.
- The sharpest annual moves came in 2025 and 2026: EBIT slumped 152.83% in 2025, then tumbled 36.24% in 2026.
- Upstream Bio's EBIT stood at -$14.3 million in 2023, then slumped by 83.66% to -$26.3 million in 2024, then sank by 75.42% to -$46.2 million in 2025, then rose by 5.53% to -$43.6 million in 2026.
- Business Quant data shows UPB's EBIT at -$43.6 million in Q1 2026, -$46.2 million in Q4 2025, and -$37.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | -42.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.37 Mn |
| Mar 31, 2026 | -43.62 Mn |
| Dec 31, 2025 | -46.17 Mn |
| Sep 30, 2025 | -37.83 Mn |
| Jun 30, 2025 | -44.35 Mn |
| Mar 31, 2025 | -32.01 Mn |
| Dec 31, 2024 | -26.32 Mn |
| Sep 30, 2024 | -18.89 Mn |
| Jun 30, 2024 | -17.54 Mn |
| Mar 31, 2024 | -15.01 Mn |
| Dec 31, 2023 | -14.33 Mn |
| Sep 30, 2023 | -9.39 Mn |